Pharmacotherapy of Depression in People with Cancer

Depression and Cancer

Volumn , Issue , 2010, Pages 151-176

  Grassi, Luigi ^a   Nanni, Maria Giulia ^a   Uchitomi, Yosuke ^b   Riba, Michelle ^c  

^a UNIVERSITY OF FERRARA   (Italy)

^b OKAYAMA UNIVERSITY   (Japan)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Clinical use of antidepressants in the treatment of depression in patients with cancer; Drug interactions with chemotherapy and anticancer agents; Monoamine oxidase inhibitors (MAOIs); Pharmacotherapy of depression in people with cancer; Selective oestrogen receptor modulator (SERM); Selective serotonin reuptake inhibitors (SSRIs); The use of antidepressants for the treatment of other symptoms in cancer patients; They include tricyclics (TCAs); Use of antidepressants and risk of cancer

Indexed keywords

EID: 84155166834     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470972533.ch7     Document Type: Chapter

References (114)

1. McDaniel, J.S., Musselman, D.L., Porter, M.R. et al. (1995) Depression in patients with cancer. Diagnosis, biology, and treatment. Arch. Gen. Psychiatry, 52, 89-99.
2. Chochinov, H.M. (2001) Depression in cancer patients. Lancet Oncol., 2, 499-505.
3. Massie, M.J. (2004) Prevalence of depression in patients with cancer. J. Natl. Cancer Inst. Monogr., 32, 57-71.
4. Grassi, L., Holland, J.C., Johansen, C. et al. (2005) Psychiatric concomitants of cancer, screening procedures, and training of health care professionals in oncology: the paradigms of psycho-oncology in the psychiatry field, in Advances in Psychiatry, vol. 2 (ed. G.N. Christodoulou), Beta Publishing, Athens, pp. 59-66.
5. Greenberg, D.B. (2004) Barriers to the treatment of depression in cancer patients. J. Natl. Cancer Inst. Monogr., 32, 127-135.
6. Spoletini, I., Gianni, W., Repetto, L. et al. (2008) Depression and cancer: an unexplored and unresolved emergent issue in elderly patients. Crit. Rev. Oncol. Hematol., 65, 143-155.
7. Newport, D.J. and Nemeroff, C.B. (1998) Assessment and treatment of depression in the cancer patient. J. Psychosom. Res., 45, 215-237.
8. National Comprehensive Cancer Network. Distress management.www. nccn.org.
9. Bultz, B.D. and Carlson, L.E. (2006) Emotional distress: the sixth vital sign - future directions in cancer care. Psychooncology, 15, 93-95.
10. Sharpe, M., Strong, V., Allen, K. et al. (2004) Major depression in outpatients attending a regional cancer centre: screening and unmet treatment needs. Br. J. Cancer, 90, 314-320.
11. Sharpe, M., Strong, V., Allen, K. et al. (2004) Management of major depression in outpatients attending a cancer centre: a preliminary evaluation of a multicomponent cancer nurse-delivered intervention. Br. J. Cancer, 90, 310-313.
12. Strong, V., Waters, R., Hibberd, C. et al. (2008) Management of depression for people with cancer (SMaRT oncology 1): a randomised trial. Lancet, 372, 40-48.
13. Shimizu, K., Ishibashi, Y., Umezawa, S., et al. Feasibility and usefulness of the 'Distress Screening Program in Ambulatory Care' in clinical oncology practice. Psychooncology (in press).
14. Grassi, L. and Riba, M. (2009) New frontiers and challenges of psychiatry in oncology and palliative care, in Advances in Psychiatry, vol. 3 (eds G.N. Christodoulou, M. Jorge and J.E. Mezzich), Beta Publishers, Athens, pp. 105-114.
15. Shimizu, K., Akechi, T., Shimamoto, M. et al. (2007) Can psychiatric intervention improve major depression in very near end-of-life cancer patients? Palliat. Support Care, 5, 3-9.
16. Jaeger, H., Morrow, G.R., Carpenter, P.J. and Brescia, F. (1985) A survey of psychotropic drug utilization by patients with advanced neoplastic disease. Gen. Hosp. Psychiatry, 7, 353-360.
17. Peterson, L.G., Leipman, M. and Bongar, B. (1987) Psychotropic medications in patients with cancer. Gen. Hosp. Psychiatry, 9, 313-323.
18. Stiefel, F.C., Kornblith, A.B. and Holland, J.C. (1990) Changes in prescription patterns of psychotropic drugs for cancer patients during a 10-year period. Cancer, 65, 1048-1053.
19. Ashbury, F.D., Madlensky, L., Raich, P. et al. (2003) Antidepressant prescribing in community cancer care. Support. Care Cancer, 11, 278-285.
20. Coyne, J.C., Palmer, S.C., Shapiro, P.J. et al. (2004) Distress, psychiatric morbidity, and prescriptions for psychotropic medication in a breast cancer waiting room sample. Gen. Hosp. Psychiatry, 26, 121-128.
21. Hewitt, M. and Rowland, J.H. (2002) Mental health service use among adult cancer survivors: analyses of the National Health Interview Survey. J. Clin. Oncol., 20, 4581-4590.
22. Kadan-Lottick, N.S., Vanderwerker, L.C., Block, S.D. et al. (2005) Psychiatric disorders and mental health service use in patients with advanced cancer: a report from the Coping with Cancer Study. Cancer, 104, 2872-2881.
23. Okamura, M., Akizuki, N., Nakano, T. et al. (2008) Clinical experience of the use of a pharmacological treatment algorithm for major depressive disorder in patients with advanced cancer. Psychooncology, 17, 154-160.
24. Rayner, L., Higginson, I.J., Price, A. and Hotopf, M. (2009) The management of depression in palliative care: draft European clinical guidelines. EPCRC Depression Guideline Expert Group, London.
25. Rodin, G., Lloyd, N., Katz, M. et al. (2007) The treatment of depression in cancer patients: a systematic review. Support. Care Cancer, 15, 123-136.
26. Berney, A., Stiefel, F., Mazzocato, C. and Buclin, T. (1999) Psychopharmacology in supportive care in cancer: a review for the clinician. III. Antidepressants. Support. Care Cancer, 7, 379-385.
27. Pirl, W.F. (2004) Evidence report on the occurrence, assessment, and treatment of depression in cancer patients. J. Natl. Cancer Inst.Monogr., 32, 32-39.
28. Mago, R., Mahajan, R. and Thase, M.E. (2008) Medically serious adverse effects of newer antidepressants. Curr. Psychiatry Rep., 10, 249-257.
29. Homsi, J., Walsh, D. and Nelson, K.A. (2000) Psychostimulants in supportive care. Support. Care Cancer, 8, 385-397.
30. Lazure, K.E., Lydiatt, W.M., Denman, D. and Burke, W.J. (2009) Association between depression and survival or disease recurrence in patients with head and neck cancer enrolled in a depression prevention trial. Head Neck, 31, 888-892.
31. Albertini, R.S. and Penders, T.M. (1978) Agranulocytosis associated with tricyclics. J. Clin. Psychiatry, 39, 483-485.
32. Adams, P.C., Robinson, A., Reid, M.M. et al. (1983) Blood dyscrasias and mianserin. Postgrad. Med. J., 59, 31-33.
33. Kasper, S., Praschak-Rieder, N., Tauscher, J. andWolf, R. (1997)Ariskbenefit assessment of mirtazapine in the treatment of depression. Drug Saf., 17, 251-264.
34. Duggal, H.S. and Singh, I. (2005) Psychotropic drug-induced neutropenia. Drugs Today, 41, 517-526.
35. Steinberg, T., Roseman, M., Kasymjanova, G. et al. (2009) Prevalence of emotional distress in newly diagnosed lung cancer patients. Support. Care Cancer, 17, 1493-1497.
36. Caraceni, A. and Grassi, L. (2003) Delirium: Acute Confusional States in Palliative Medicine, Oxford University Press, Oxford.
37. Yap, K.Y., Tay,W.L., Chui,W.K. and Chan, A., Clinically relevant drug interactions between anticancer drugs and psychotropic agents. Eur. J. Cancer Care (in press).
38. Bracarda, S., Eggermont, A.M. and Samuelsson, J., Redefining the role of interferon in the treatment of malignant diseases. Eur. J. Cancer, 46, 284-97.
39. 39. Valentine, A.D. and Meyers, C.A. (2005) Neurobehavioral effects of interferon therapy. Curr. Psychiatry Rep., 7, 391-395.
40. Patten, S.B. (2006) Psychiatric side effects of interferon treatment. Curr. Drug Saf., 1, 143-150.
41. Musselman, D.L., Lawson, D.H., Gumnick, J.F. et al. (2001) Paroxetine for the prevention of depression induced by high-dose interferon alfa. N. Engl. J. Med., 344, 961-966.
42. Capuron, L., Gumnick, J.F., Musselman, D.L. et al. (2002) Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology, 26, 643-652.
43. Camacho, A. and Ng, B. (2006) Methylphenidate for alpha-interferon induced depression. J. Psychopharmacol., 20, 687-689.
44. Reddy, K.K., Lefkove, B., Chen, L.B. et al. (2008) The antidepressant sertraline downregulates Akt and has activity against melanoma cells. Pigment Cell Melanoma Res., 21, 451-456.
45. Nelson, H.D., Fu, R., Griffin, J.C. et al. (2009) Systematic review: comparative effectiveness of medications to reduce risk for primary breast cancer. Ann. Intern. Med., 151, 703-715.
46. Henry, N.L., Stearns, V., Flockhart, D.A. et al. (2008) Drug interactions and pharmacogenomics in the treatment of breast cancer and depression. Am. J. Psychiatry, 165, 1251-1255.
47. Jin, Y., Desta, Z., Stearns, V. et al. (2005) CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J. Natl. Cancer Inst., 97 30-39.
48. Goetz, M.P., Rae, J.M., Suman, V.J. et al. (2005) Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flushes. J. Clin. Oncol., 23, 9312-9318.
49. Stearns, V., Johnson, M.D., Rae, J.M. et al. (2003) Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J. Natl. Cancer Inst., 95, 1758-1764.
50. Kelly, C.M., Juurlink, D.N., Gomes, T., et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ (in press).
51. Lash, T.L., Pedersen, L., Cronin-Fenton, D. et al. (2008) Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram. Br. J. Cancer, 99, 616-621.
52. Weekes, J., Lam, A.K., Sebesan, S. and Ho, Y.H. (2009) Irinotecan therapy and molecular targets in colorectal cancer: a systemic review. World J. Gastroenterol., 15, 3597-3602.
53. Mathijssen, R.H., Verweij, J., de Bruijn, P. et al. (2002) Effects of St. John's Wort on irinotecan metabolism. J. Natl. Cancer Inst., 94, 1247-1249.
54. Richards, S., Umbreit, J.N., Fanucchi, M.P. et al. (2003) Selective serotonin reuptake inhibitor-induced rhabdomyolysis associated with irinotecan. South Med. J., 96, 1031-1033.
55. Kim, H.F. and Fisch, M.J. (2006) Antidepressant use in ambulatory cancer patients. Curr. Oncol. Rep., 8, 275-281.
56. Lee, J., Franz, L. and Goforth, H.W. (2009) Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine. Psychosomatics, 50, 638-639.
57. Takeshita, J. and Litzinger, M.H. (2009) Serotonin syndrome associated with tramadol. Prim. Care Companion J. Clin. Psychiatry, 11, 273.
58. Brown, E.S. and Suppes, T. (1998) Mood symptoms during corticosteroid therapy: a review. Harv. Rev. Psychiatry, 5, 239-246.
59. Brown, E.S. and Chandler, P.A. (2001) Mood and cognitive changes during systemic corticosteroid therapy. Prim. Care Companion J. Clin. Psychiatry, 3, 17-21.
60. Wada, K., Yamada, N., Sato, T. et al. (2001) Corticosteroid-induced psychotic and mood disorders: diagnosis defined by DSM-IV and clinical pictures. Psychosomatics, 42, 461-466.
61. Stiefel, F.C., Breitbart,W.S. and Holland, J.C. (1989) Corticosteroids in cancer: neuropsychiatric complications. Cancer Invest., 7, 479-491.
62. Goudas, L.C., Bloch, R., Gialeli-Goudas, M. et al. (2005) The epidemiology of cancer pain. Cancer Invest., 23, 182-190.
63. van den Beuken-van Everdingen, M.H., de Rijke, J.M., Kessels, A.G. et al. (2007) Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann. Oncol., 18, 1437-1449.
64. Breivik, H., Cherny, N., Collett, B. et al. (2009) Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes. Ann. Oncol., 20, 1420-1433.
65. Bair, M.J., Robinson, R.L., Katon,W. and Kroenke, K. (2003) Depression and pain comorbidity: a literature review. Arch. Intern. Med., 163, 2433-2445.
66. Breitbart, W., Payne, D. and Passik, S. (2004) Psychological and psychiatric interventions in pain control, in Oxford Textbook of Palliative Medicine, 3rd edn (eds. D. Doyle, G. Hanks, N. Cherny and K. Calman), Oxford University Press, New York, pp. 424-438.
67. Gagliese, L., Gauthier, L.R. and Rodin, G. (2007) Cancer pain and depression: a systematic review of age-related patterns. Pain Res. Manag., 12, 205-211.
68. Laird, B.J., Boyd, A.C., Colvin, L.A. and Fallon, M.T. (2009) Are cancer pain and depression interdependent? A systematic review. Psychooncology, 18, 459-464.
69. Barkin, R.L. and Fawcett, J. (2000) The management challenges of chronic pain: the role of antidepressants. Am. J. Ther., 7, 31-47.
70. Kroenke, K., Krebs, E.E. and Bair, M.J. (2009) Pharmacotherapy of chronic pain: a synthesis of recommendations from systematic reviews. Gen. Hosp. Psychiatry, 31, 206-219.
71. Blier, P. and Abbott, F.V. (2001) Putative mechanisms of action of antidepressant drugs in affective and anxiety disorders and pain. J. Psychiatry Neurosci., 26, 37-43.
72. Lussier, D., Huskey, A.G. and Portenoy, R.K. (2004) Adjuvant analgesics in cancer pain management. Oncologist, 9, 571-591.
73. Hickey, M., Saunders, C., Partridge, A. et al. (2008) Practical clinical guidelines for assessing and managing menopausal symptoms after breast cancer. Ann. Oncol., 19, 1669-1680.
74. Loprinzi, C.L., Sloan, J.A., Perez, E.A. et al. (2002) Phase III evaluation of fluoxetine for treatment of hot flushes. J. Clin. Oncol., 20, 1578-1583.
75. Stearns, V., Slack, R., Greep, N. et al. (2005) Paroxetine is an effective treatment for hot flushes: results from a prospective randomized clinical trial. J. Clin. Oncol., 23, 6919-6930.
76. Kimmick, G.G., Lovato, J., McQuellon, R. et al. (2006) Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flushes in women with early stage breast cancer taking tamoxifen. Breast J., 12, 114-122.
77. Carpenter, J.S., Storniolo, A.M., Johns, S. et al. (2007) Randomized, double-blind, placebo-controlled crossover trials of venlafaxine for hot flushes after breast cancer. Oncologist, 12, 124-135.
78. Loibl, S., Schwedler, K., von Minckwitz, G. et al. (2007) Venlafaxine is superior to clonidine as treatment of hot flushes in breast cancer patients-a double-blind, randomized study. Ann. Oncol., 18, 689-693.
79. Buijs, C., Mom, C.H., Willemse, P.H. et al. (2009) Venlafaxine versus clonidine for the treatment of hot flushes in breast cancer patients: a double-blind, randomized cross-over study. Breast Cancer Res. Treat., 115, 573-580.
80. Biglia, N., Kubatzki, F., Sgandurra, P. et al. (2007) Mirtazapine for the treatment of hot flushes in breast cancer survivors: a prospective pilot trial. Breast J., 13, 490-495.
81. Stearns, V. (2004) Management of hot flushes in breast cancer survivors and men with prostate cancer. Curr. Oncol. Rep., 6, 285-290.
82. Naoe, M., Ogawa, Y., Shichijo, T. et al. (2006) Pilot evaluation of selective serotonin reuptake inhibitor antidepressants in hot flush patients under androgen-deprivation therapy for prostate cancer. Prostate Cancer Prostatic Dis., 9, 275-278.
83. Barton, D.L., Loprinzi, C.L., Novotny, P. et al. (2003) Pilot evaluation of citalopram for the relief of hot flushes. J. Support Oncol., 1, 47-51.
84. Irani, J., Salomon, L., Oba, R., et al. Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial. Lancet Oncol. 11, 147-54.
85. Zylicz, Z., Smits, C. and Krajnik, M. (1998) Paroxetine for pruritus in advanced cancer. J. Pain Symptom Manag., 16, 121-124.
86. Zylicz, Z., Krajnik, M., Sorge, A.A. and Costantini, M. (2003) Paroxetine in the treatment of severe non-dermatological pruritus: a randomized, controlled trial. J. Pain Symptom Manag., 26, 1105-1112.
87. Davis, M.P., Frandsen, J.L., Walsh, D. et al. (2003) Mirtazapine for pruritus. J. Pain Symptom Manag., 25, 288-291.
88. Demierre, M.F. and Taverna, J. (2006) Mirtazapine and gabapentin for reducing pruritus in cutaneous T-cell lymphoma. J. Am. Acad. Dermatol., 55, 543-544.
89. Schwartzberg, L. (2006) Chemotherapy-induced nausea and vomiting: state of the art in 2006. J. Support Oncol., 4 (Suppl. 1), 3-8.
90. Lohr, L. (2008) Chemotherapy-induced nausea and vomiting. Cancer J., 14, 85-93.
91. Critchley, P., Plach, N., Grantham, M. et al. (2001) Efficacy of haloperidol in the treatment of nausea and vomiting in the palliative patient: a systematic review. J. Pain Symptom Manag., 22, 631-634.
92. Navari, R.M. (2009) Pharmacological management of chemotherapyinduced nausea and vomiting: focus on recent developments. Drugs, 69, 515-533.
93. Tan, L., Liu, J., Liu, X. et al. (2009) Clinical research of olanzapine for prevention of chemotherapy-induced nausea and vomiting. J. Exp. Clin. Cancer Res., 28, 131.
94. Kim, S.W., Shin, I.S., Kim, J.M. et al. (2008) Effectiveness of mirtazapine for nausea and insomnia in cancer patients with depression. Psychiatry Clin. Neurosci., 62, 75-83.
95. Riechelmann, R.P., Burman, D., Tannock, I.F., et al. Phase II trial of mirtazapine for cancer-related cachexia and anorexia. Am. J. Hosp. Palliat. Care (in press).
96. Breitbart, W. and Alici-Evcimen, Y. (2007) Update on psychotropic medications for cancer-related fatigue. J. Natl. Compr. Canc. Netw., 5, 1081-1091.
97. Minton, O., Richardson, A., Sharpe, M. et al. (2008) A systematic review and meta-analysis of the pharmacological treatment of cancerrelated fatigue. J. Natl. Cancer Inst., 100, 1155-1166.
98. Morrow, G.R., Hickok, J.T., Roscoe, J.A. et al. (2003) Differential effects of paroxetine on fatigue and depression: a randomized, double- blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program. J. Clin. Oncol., 21, 4635-4641.
99. Moss, E.L., Simpson, J.S., Pelletier, G. and Forsyth, P. (2006) An openlabel study of the effects of bupropion SR on fatigue, depression and quality of life of mixed-site cancer patients and their partners. Psychooncology, 15, 259-267.
100. Cullum, J.L., Wojciechowski, A.E., Pelletier, G. and Simpson, J.S. (2004) Bupropion sustained release treatment reduces fatigue in cancer patients. Can. J. Psychiatry, 49 (2), 139-144.
101. Kelly, J.P., Rosenberg, L., Palmer, J.R. et al. (1999) Risk of breast cancer according to use of antidepressants, phenothiazines, and antihistamines. Am. J. Epidemiol., 150, 861-868.
102. Cotterchio, M., Kreiger, N., Darlington, G. and Steingart, A. (2000) Antidepressant medication use and breast cancer risk. Am. J. Epidemiol., 151, 951-957.
103. Bahl, S., Cotterchio, M. and Kreiger, N. (2003) Use of antidepressant medications and the possible association with breast cancer risk. A review. Psychother. Psychosom., 72, 185-194.
104. Wang, P.S., Walker, A.M., Tsuang, M.T. et al. (2001) Antidepressant use and the risk of breast cancer: a non-association. J. Clin. Epidemiol., 54, 728-734.
105. Lawlor, D.A., Juni, P., Ebrahim, S. and Egger, M. (2003) Systematic review of the epidemiologic and trial evidence of an association between antidepressant medication and breast cancer. J. Clin. Epidemiol., 56, 155-163.
106. Wernli, K.J., Hampton, J.M., Trentham-Dietz, A. and Newcomb, P.A. (2009) Antidepressant medication use and breast cancer risk. Pharmacoepidemiol. Drug Saf., 18, 284-290.
107. Haukka, J., Sankila, R., Klaukka, T. et al. (2009) Incidence of cancer and antidepressant medication: record linkage study. Int. J. Cancer, 126, 285-296.
108. Tutton, P.J. and Barkla, D.H. (1982) Influence of inhibitors of serotonin uptake on intestinal epithelium and colorectal carcinomas. Br. J. Cancer, 46, 260-265.
109. Argov, M., Kashi, R., Peer, D. and Margalit, R. (2009) Treatment of resistant human colon cancer xenografts by a fluoxetine-doxorubicin combination enhances therapeutic responses comparable to an aggressive bevacizumab regimen. Cancer Lett., 274, 118-125.
110. Xu,W., Tamim, H., Shapiro, S. et al. (2006) Use of antidepressants and risk of colorectal cancer: a nested case-control study. Lancet Oncol., 7, 301-308.
111. Coogan, P.F., Strom, B.L. and Rosenberg, L. (2009) Antidepressant use and colorectal cancer risk. Pharmacoepidemiol Drug Saf., 18, 1111-1114.
112. Fabbri, S., Fava, G.A., Sirri, L. andWise, T.N. (2007) Development of a new assessment strategy in psychosomatic medicine: the Diagnostic Criteria for Psychosomatic Research, in Psychological Factors Affecting Medical Conditions. A New Classification for DSM-V (eds. P. Porcelli and N. Sonino), Karger, Basel, pp. 1-20.
113. Grassi, L., Biancosino, B., Marmai, L. et al. (2007) Psychological factors affecting oncology conditions, in Psychological Factors Affecting Medical Conditions. A New Classification for DSM-V (eds. P. Porcelli and N. Sonino), Karger, Basel, pp. 57-71.
114. Williams, S. and Dale, J. (2006) The effectiveness of treatment for depression/depressive symptoms in adults with cancer: a systematic review. Br. J. Cancer, 94, 372-390.